These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 19620476)
21. The role of adjuvant interferon in high risk melanoma patients. Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951 [No Abstract] [Full Text] [Related]
22. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805 [TBL] [Abstract][Full Text] [Related]
23. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse. Gale DM; Kiley KE Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250 [TBL] [Abstract][Full Text] [Related]
24. Update on the role of adjuvant interferon for high risk melanoma. Agarwala SS; Kirkwood JM Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931 [TBL] [Abstract][Full Text] [Related]
25. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment. Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673 [TBL] [Abstract][Full Text] [Related]
26. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Bajetta E Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604 [No Abstract] [Full Text] [Related]
27. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686 [TBL] [Abstract][Full Text] [Related]